Goldman Sachs Group Inc Sab Biotherapeutics, Inc. Transaction History

Goldman Sachs Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	SELL	$0.13 - $12.4 $239 - $22,865	-1,844 Reduced 12.75%	12,618 $9,000
Q3 2022 Nov 10, 2022	SELL	$0.13 - $12.4 $239 - $22,865	-1,844 Reduced 12.75%	12,618 $0
Q2 2022 May 14, 2024	BUY	$1.11 - $3.46 $16,052 - $50,038	14,462 New	14,462 $21,000
Q2 2022 Aug 15, 2022	SELL	$1.11 - $3.46 $1,145 - $3,570	-1,032 Reduced 6.66%	14,462 $21,000
Q1 2022 May 16, 2022	BUY	$1.78 - $8.5 $1,788 - $8,542	1,005 Added 6.94%	15,494 $58,000
Q4 2021 Feb 14, 2022	BUY	$7.3 - $11.24 $105,769 - $162,856	14,489 New	14,489 $113,000

529K

Ticker SABS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,030,900
Market Cap $111M
Description
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases ...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.